Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors

摘要: Introduction Previous exploratory analysis of epidermal growth factor receptor (EGFR) mutational status in tumor samples from randomized clinical studies suggested that patients with activating mutation the EGFR had better survival than those harboring wild-type EGFR. Methods We analyzed sequence advanced stage non-small cell lung cancer previously participated treatment trials. Responses to chemotherapy and mutation-positive or -negative were compared. Results Tumor 122 available for analysis. was present 58 (47.5%). In 105 IIIB/IV patients, there a nonstatistically significant trend toward higher response rate mutated (44.6% versus 30.6%, p = 0.162). Female, never-smoking, adenocarcinoma lived longer male (p 0.0139), smoking 0.0045), nonadenocarcinoma 0.0151) patients. There no difference 0.2159). progression-free first-line between (6.6 months 6.1 months). Conclusion is gene not predictive biomarker overall cytotoxic East Asians cancer.